Ethyl-EPA Treatment of Prodromal Patients

Schizophrenia Prodrome Clinical Trial

Official title:

Ethyl-EPA Treatment of Prodromal Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00634361
• Other study ID #: LA01.03.0011
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: March 6, 2008
• Last updated: May 21, 2014
• Start date: September 2001
• Est. completion date: August 2005

Study information

• Verified date: May 2014
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Other known NCT identifiers

• NCT00237835

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: August 2005
• Est. primary completion date: August 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 14 Years to 35 Years

Eligibility

Inclusion Criteria:

• meets criteria for schizophrenia prodrome

Exclusion Criteria:

• any lifetime antipsychotic treatment

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia Prodrome

Intervention

Drug:
• ethyl-eicosapentaenoic acid
2 mg per day

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Yale University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	conversion to psychosis		one year	No